2025 Annual Report of Independent Director Shi Jing
In 2025, I served as an independent director for the fifth and sixth terms of the Board of Directors of Hefei Lifang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"). As an independent director, I strictly followed the requirements of laws and regulations such as the "Company Law of the People's Republic of China," the "Administrative Measures for Independent Directors of Listed Companies," the "Shenzhen Stock Exchange Main Board Listed Company Normative Operation Guide No. 1," the "Code of Corporate Governance for Listed Companies," and the "Articles of Association" and "Independent Director Work System." I performed my duties with integrity, diligence, responsibility, and loyalty, actively safeguarding the company's interests and the legitimate rights and interests of shareholders, and effectively fulfilling the role of an independent director.
Here is my report on my performance in 2025:
I. Basic Information
I, Shi Jing, am a male Chinese national with no permanent overseas residency. I hold a Master of Laws degree and am a certified M&A advisor, a financial insurance and securities lawyer, and a senior lawyer. I have previously worked at Hefei Water Supply Group and Anhui Shangyi Law Firm. I am currently the Director/Partner of Anhui Hongqi Law Firm, a representative of the 10th National Lawyers Congress, a standing director of the Anhui Lawyers Association, vice president of the Hefei Lawyers Association, a visiting professor at Anhui University of Finance and Economics, and a legal advisor to the Hefei Municipal People's Government. I have received numerous honors, including "National Outstanding Communist Party Member in the Legal Industry," "Top Ten Lawyers in Anhui Province," "First Anhui Top Ten Public Welfare Lawyers," "Outstanding Lawyer in Anhui Province," and "Top Ten Lawyers in Hefei." I have served as an independent director of the Company since November 15, 2023.
During my tenure, my position complied with the requirements of the "Administrative Measures for Independent Directors of Listed Companies" and other relevant laws and regulations regarding independence, and there were no circumstances that affected my independence.
II. Overview of Annual Performance
(I) Attendance at Meetings
In 2025, the fifth Board of Directors held 6 meetings, and the sixth Board of Directors held 3 meetings. I attended all of them in person and did not entrust other directors to attend on my behalf, nor were there any absences.
In 2025, the Company held a total of 3 shareholder meetings/general meetings, including 1 annual general meeting and 2 extraordinary general meetings/general meetings. I attended all of them in person, with no absences.
I carefully reviewed all proposals submitted to the Board of Directors and shareholder meetings, communicated fully with the company's management, and offered some constructive suggestions. I exercised my voting rights with prudence, and there were no matters I objected to or abstained from.
(II) Participation in the Work of the Board's Special Committees
The Company's Board of Directors has established an Audit Committee, a Strategy Committee, a Nomination Committee, and a Remuneration and Assessment Committee. During the reporting period, I served as the Chairman of the Remuneration and Assessment Committee and a member of the Audit Committee and Nomination Committee. I strictly performed my duties in accordance with the requirements of the "Articles of Association" and the work rules of the special committees, promoting the standardized operation of the company's board committees and providing constructive opinions on the company's healthy and sustainable development from a professional perspective. As the Chairman of the Remuneration and Assessment Committee in 2025, I presided over 4 meetings of the Remuneration and Assessment Committee, reviewing and voting on matters such as the company's equity incentive plan. As a member of the special committees, I attended 6 meetings of the Audit Committee and 3 meetings of the Nomination Committee.